I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.
Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ: CRSP) , Invitae (NYSE: NVTA) , and Personalis (NASDAQ: PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.
Image source: Getty Images.
For further details see:
Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought